Your browser doesn't support javascript.
loading
Real-World Evidence to Support EU Regulatory Decision Making-Results From a Pilot of Regulatory Use Cases.
Prilla, Stefanie; Groeneveld, Sophie; Pacurariu, Alexandra; Restrepo-Méndez, María Clara; Verpillat, Patrice; Torre, Carla; Gartner, Christian; Mol, Peter G M; Naumann-Winter, Frauke; Breen, Kieran C; Gault, Nathalie; Gross-Martirosyan, Liana; Benchetrit, Sylvie; Aylward, Brian; Stoyanova-Beninska, Violeta; O'Donovan, Maura; Straus, Sabine; Kjaer, Jesper; Arlett, Peter.
Afiliación
  • Prilla S; Data Analytic Analytics and Methods Taskforce, European Medicines Agency, Amsterdam, The Netherlands.
  • Groeneveld S; Data Analytic Analytics and Methods Taskforce, European Medicines Agency, Amsterdam, The Netherlands.
  • Pacurariu A; Data Analytic Analytics and Methods Taskforce, European Medicines Agency, Amsterdam, The Netherlands.
  • Restrepo-Méndez MC; Data Analytic Analytics and Methods Taskforce, European Medicines Agency, Amsterdam, The Netherlands.
  • Verpillat P; Data Analytic Analytics and Methods Taskforce, European Medicines Agency, Amsterdam, The Netherlands.
  • Torre C; Departamento de Farmácia, Farmacologia e Tecnologias em Saúde, Faculdade de Farmácia, Universidade de Lisboa, Lisbon, Portugal.
  • Gartner C; Austrian Agency for Health and Food Safety, Vienna, Austria.
  • Mol PGM; Department of Clinical Pharmacy and Pharmacology, University Medical Centre Groningen, Groningen, The Netherlands.
  • Naumann-Winter F; Dutch Medicines Evaluation Board, CBG-MEB, Utrecht, The Netherlands.
  • Breen KC; Federal Institute for Drugs and Medical Devices, Bonn, Germany.
  • Gault N; St Andrew's Healthcare, Northampton, UK.
  • Gross-Martirosyan L; French National Agency for Medicines and Health Products Safety, Saint-Denis, France.
  • Benchetrit S; Dutch Medicines Evaluation Board, CBG-MEB, Utrecht, The Netherlands.
  • Aylward B; French National Agency for Medicines and Health Products Safety, Saint-Denis, France.
  • Stoyanova-Beninska V; Health Products Regulatory Authority, Dublin, Ireland.
  • O'Donovan M; Dutch Medicines Evaluation Board, CBG-MEB, Utrecht, The Netherlands.
  • Straus S; Health Products Regulatory Authority, Dublin, Ireland.
  • Kjaer J; Dutch Medicines Evaluation Board, CBG-MEB, Utrecht, The Netherlands.
  • Arlett P; Department of Medical Informatics, Erasmus Medical Center, Erasmus MC, Rotterdam, The Netherlands.
Clin Pharmacol Ther ; 2024 Jul 04.
Article en En | MEDLINE | ID: mdl-38962830
ABSTRACT
Studies using real-world data (RWD) can complement evidence from clinical trials and fill evidence gaps during different stages of a medicine's lifecycle. This review presents the experience resulting from the European Medicines Agency (EMA) pilot to generate RWE to support evaluations by EU regulators and down-stream decision makers from September 2021 to February 2023. A total of 61 research topics were identified for RWE generation during this period, covering a wide range of research questions, primarily generating evidence on medicines safety (22, 36%), followed by questions on the design and feasibility of clinical trials (11, 18%), drug utilization (10, 16%), clinical management (10, 16%), and disease epidemiology. A significant number of questions were related to the pediatric population and/or rare diseases. A total of 27 regulatory-led RWD studies have been conducted. Most studies were descriptive and aimed at estimating incidence and prevalence rates of clinical outcomes including adverse events or to evaluate medicines utilization. The review highlights key learnings to guide further efforts to enable the use and establish the value of real-world evidence (RWE) for regulatory decisions. For instance, there is a need to access additional fit-for-purpose and representative data, and to explore further means to provide timely evidence that meets regulatory timelines. The need for early interactions and close collaboration with study requesters, e.g., from the Agency's scientific Committees, to better understand the research question is equally important. Finally, the review provides our perspective on the way forward to maximize the potential of regulatory-led RWE generation.

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Clin Pharmacol Ther Año: 2024 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Clin Pharmacol Ther Año: 2024 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Estados Unidos